Skip to main content
Log in

Experimental Design Approach for Selective Separation of Vilazodone HCl and Its Degradants by LC-PDA and Characterization of Major Degradants by LC/QTOF–MS/MS

  • Original
  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

A selective, rapid, accurate and precise stability-indicating RP-HPLC method was developed for monitoring vilazodone in the presence of its degradation products (DPs) in API and pharmaceutical dosages. Chromatographic separation was achieved using a Grace phenyl C18 column (250 × 4.6 mm, 5 µm particle size) at a flow rate of 1.0 mL min−1 with a linear gradient elution of ammonium acetate buffer (10 mM, pH 5.0 adjusted by acetic acid) with acetonitrile as the mobile phase. Detection was performed at 240 nm. The chromatographic conditions were optimized by the design of experiments to obtain the best possible separation with a minimum number of trials. A face-centered central composite design (three levels for each factor) was employed for optimization, and an interaction of the independent variables (pH of mobile phase, column temperature and  % of organic modifier) on the resolution of critical pairs was studied. The drug was subjected to the stress conditions of hydrolytic (acid, base and neutral), oxidative, thermal and photolytic degradation. It was found to be degraded significantly in hydrolytic (basic and acid) and oxidative conditions, while it was stable in neutral hydrolytic, thermal and photolytic conditions. LC-QTOF/MS/MS studies were carried out to characterize the major DPs. The method was fully validated for selectivity, linearity, accuracy, precision and robustness in compliance with ICH guideline Q2 (R1).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Scheme 1
Scheme 2
Scheme 3

Similar content being viewed by others

References

  1. Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005) Arch Gen Psychiatry 62:1097

    Article  Google Scholar 

  2. Kessler RC, Berglund P, Demler O (2003) JAMA 289:3095–3105

    Article  Google Scholar 

  3. Jones J (2012) PharmaNote 27

  4. FDA (1987) Guideline for submitting documentation for the stability of human drugs and biologics. Food and Drug Administration, Rockville

    Google Scholar 

  5. International Conference on Harmonization (ICH) Guideline of Technical Requirements for Registration of Pharmaceuticals for Human Use (2000) Q1A (R2) stability testing of new drug substances and products. International Conference on Harmonisation, IFPMA, Geneva

    Google Scholar 

  6. Bakshi M, Singh S (2002) J Pharm Biomed Anal 28:1011–1040

    Article  CAS  Google Scholar 

  7. US Food and Drug Administration (FDA) (2007) Department of Health and Human Services, pharmaceutical quality for the 21st century a risk-based approach progress report. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm128080.html

  8. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (2009) Topic Q8 (R2): pharmaceutical development. ICH, Geneva

    Google Scholar 

  9. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) Topic Q9: quality risk management. ICH, Geneva

    Google Scholar 

  10. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (2008) Topic Q10: pharmaceutical quality system. ICH, Geneva

    Google Scholar 

  11. Karmarkar S, Garber R, Genchanok Y, George S, Yang X, Hammond R (2011) J Chromatogr Sci 49:439–446

    Article  CAS  Google Scholar 

  12. Schmidt AH, Molnar I (2013) J Pharm Biomed Anal 78–79:65–74

    Article  Google Scholar 

  13. Garg LK, Reddy VS, Sait SS, Krishnamurthy T, Vali SJ, Reddy AM (2013) Chromatographia 76:1697–1706

    Article  CAS  Google Scholar 

  14. Smajic M, Vujic Z, Mulavdic N, Brboric J (2013) Chromatographia 76:419–425

    Article  CAS  Google Scholar 

  15. Srinubabu G, Jaganbabu K, Sudharani B, Venugopal K, Girizasankar G, Rao J (2006) Chromatographia 64:95–100

    Article  CAS  Google Scholar 

  16. Harang V, Karlsson A, Josefson M (2001) Chromatographia 54:703–709

    Article  CAS  Google Scholar 

  17. Dincel A, Basci NE (2007) Chromatographia 66:81–85

    Article  Google Scholar 

  18. Snyder LR, Kirkland JJ, Dolan JW (1997) Practical HPLC method development. Wiley, New Jersey, p 240

    Book  Google Scholar 

  19. Snyder LR, Kirkland JJ, Glajch JL (1997) Practical HPLC method development. Wiley, New York, pp 411–415

    Book  Google Scholar 

  20. Beg QK, Sahai V, Gupta R (2003) Process Biochem 39:203–209

    Article  CAS  Google Scholar 

  21. Kalariya PD, Namdev D, Srinivas R, Gananadhamu S (2014) J Saudi Chem Soc. doi:10.1016/j.jscs.2014.1004.1004

  22. Kalariya PD, Raju B, Borkar RM, Namdev D, Gananadhamu S, Nandekar PP, Sangamwar AT, Srinivas R (2014) J Mass Spectrom 49:380–391

    Article  CAS  Google Scholar 

  23. Namdev D, Borkar RM, Raju B, Kalariya PD, Rahangdale VT, Gananadhamu S, Srinivas R (2014) J Pharm Biomed Anal 88:245–255

    Article  CAS  Google Scholar 

  24. Talluri MVN, Kandimalla NR, Bandu R, Chundi D, Marupaka R, Ragampeta S (2013) J Pharm Anal 4:107–116

    Article  Google Scholar 

  25. Mohan A, Shanmugavel S, Goyal A, Venkataraman BR, Saravanan D (2009) Chromatographia 69:1211–1220

    Article  CAS  Google Scholar 

  26. Zhang Y, Wang Z, Ma Z, Cheng Y (2008) Chromatographia 68:903–909

    Article  CAS  Google Scholar 

  27. Qi M, Wang P, Xiao G (2004) Chromatographia 59:373–379

    CAS  Google Scholar 

  28. Dyakonov T, Muir A, Nasri H, Toops D, Fatmi A (2010) Pharm Res 27:1318–1324

    Article  CAS  Google Scholar 

  29. Saeed MS, Ibrahim MN, Ahmed MEE (2012) Der Chemica Sinica 3:292–298

    CAS  Google Scholar 

  30. Sridhar L, Karthikraj R, Murty M, Raju NP, Vairamani M, Prabhakar S (2013) Int J Mass Spectrom 333:15–20

    Article  CAS  Google Scholar 

  31. Bremner JB, Browne EJ, Davies PE, Thuc LV (1980) Aust J Chem 33:833–841

    Article  CAS  Google Scholar 

  32. ICH Q2 (R1) International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) Topic Q2 (R1): validation of analytical procedures: text and methodology

Download references

Acknowledgments

The authors wish to thank Dr. Ahmed Kamal, project director, NIPER, Hyderabad, India, and Dr. M. Lakshmi Kantam, Director, IICT, Hyderabad, for facilities and their cooperation. P.K. is thankful to the Ministry of Pharmaceuticals, New Delhi, for the award of a Junior Research Fellowship.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. V. N. Kumar Talluri.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supporting information (PDF 686 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalariya, P.D., Talluri, M.V.N.K. & Ragampeta, S. Experimental Design Approach for Selective Separation of Vilazodone HCl and Its Degradants by LC-PDA and Characterization of Major Degradants by LC/QTOF–MS/MS. Chromatographia 77, 1299–1313 (2014). https://doi.org/10.1007/s10337-014-2739-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10337-014-2739-0

Keywords

Navigation